McCormick & Co. (MKC) Has Leaped To A New High On Strong Q2 Earnings
McCormick & Co. (MKC) reported second quarter EPS of $1.02 Thursday morning, up from $0.82 a year ago. Street expectations were for EPS of $0.93.
Source: RTTNews
FDA Approves Aurinia Pharmaceuticals' (Nasdaq: AUPH / TSX: AUP) LUPKYNIS (voclosporin) for Adult Patients with Active Lupus Nephritis




